• IDEAYA Biosciences entered a clinical collaboration with Genentech to test IDE892 with KRAS G12D inhibitor GDC-7035 (RG6620) in PDAC.
• Trial targets patients with MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma; Genentech will sponsor the study under joint governance.
• IDEAYA will supply IDE892; each party keeps commercial rights to its compound for monotherapy or combination use.
• Companies estimate MTAP deletions and KRAS G12D mutations co-occur in up to about 15% of PDAC patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608190600PR_NEWS_USPR_____SF28966) on August 19, 2026, and is solely responsible for the information contained therein.